HC Wainwright restated their neutral rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $1.25 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Akebia Therapeutics in a research report on Friday, March […]
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 6,680,000 shares, a decrease of 20.3% from the February 28th total of 8,380,000 shares. Based on an average daily trading volume, of 2,260,000 shares, the days-to-cover ratio […]
Equities researchers at StockNews.com started coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock. Akebia Therapeutics Stock Performance NASDAQ:AKBA opened at $0.58 on Monday. The stock has a 50-day simple moving average […]
Research analysts at StockNews.com began coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a report issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Several other research firms also recently weighed in on AKBA. Piper Sandler downgraded Akebia Therapeutics from an “overweight” rating to a “neutral” rating […]
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) have been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in […]